OX2R targeted agonists address core loss of ~70,000 hypocretin neurons in lateral hypothalamus.
Consolidating daytime arousal without peripheral sympathetic tachycardia or tremor.
Modulating glymphatic clearance, brown adipose thermogenesis, and motivation circuits.